Caris Life Sciences Target price 2025 - Analyst rating & recommendation
Caris Life Sciences Classifications & Recommendation:
Caris Life Sciences Price Target
| Target Price | $40.29 |
| Price | $28.86 |
| Potential |
39.61%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Caris Life Sciences 2026 .
The average Caris Life Sciences target price is $40.29.
This is
39.61%
register free of charge
$47.25
63.72%
register free of charge
$36.36
25.99%
register free of charge
|
|
| A rating was issued by 12 analysts: 11 Analysts recommend Caris Life Sciences to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Caris Life Sciences stock has an average upside potential 2026 of
39.61%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 412.26 | 678.81 |
| 34.67% | 64.66% | |
| EBITDA Margin | -62.34% | -1.92% |
| 40.19% | 96.92% | |
| Net Margin | -91.75% | -106.14% |
| 39.27% | 15.68% |
9 Analysts have issued a sales forecast Caris Life Sciences 2025 . The average Caris Life Sciences sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Caris Life Sciences EBITDA forecast 2025. The average Caris Life Sciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Caris Life Sciences Analysts have issued a net profit forecast 2025. The average Caris Life Sciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.36 | -2.55 |
| 18.07% | 87.50% | |
| P/E | negative | |
| EV/Sales | 11.21 |
9 Analysts have issued a Caris Life Sciences forecast for earnings per share. The average Caris Life Sciences EPS is
This results in the following potential growth metrics and future valuations:
Caris Life Sciences...
Current Caris Life Sciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Dec 02 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Jul 15 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jul 14 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jul 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Dec 02 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 13 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 13 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 13 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Jul 15 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jul 14 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
